Nasdaq:US$16.49 (+0.04) | HKEX:HK$26.10 (-0.45) | AIM:£2.71 (+0.01)
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2014-06-03

ASCO 2014: A phase 1b study of VEGFR inhibitor fruquintinib in patients with pretreated advanced colorectal cancer